Iterion Therapeutics announced that two abstracts featuring its first-in-class TBL1 inhibitor, tegavivint, will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
Morning Overview on MSN
Researchers find some cancer drugs work differently than their stated targets
As of spring 2026, a cancer drug that has spent years in clinical development as a Wnt/beta-catenin pathway blocker has been ...
(A) The heatmap showing the differential expression of the Wnt proteins and the Wnt target genes between the GTEx cortex (n = 199) and TCGA-GBM (n = 173) datasets. (B) The spatial transcriptomic data ...
Fig. 1: Wnt ligand expression promotes liver metastasis of gastric cancer. Two gastric organoid lines, KTP and WKTP were established from mouse stomach epithelium. KTP organoids carry driver mutations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results